openheart Bias associated with left ventricular quantification by multimodality imaging: a systematic review and meta-analysis

Marzia Rigolli,^{1,2} Sulakchanan Anandabaskaran,¹ Jonathan P Christiansen,¹ Gillian A Whalley^{1,3}

ABSTRACT

Purpose: Cardiac MR (CMR) is the gold standard for left ventricular (LV) quantification. However, twodimensional echocardiography (2DE) is the most common approach, and both three-dimensional echocardiography (3DE) and multidetector CT (MDCT) are increasingly available. The clinical significance and interchangeability of these modalities remains underinvestigated. Therefore, we undertook a systemic review to evaluate the accuracy and absolute bias in LV quantification of all the commonly available noninvasive imaging modalities (2DE, CE-2DE, 3DE, MDCT) compared to cardiac MR (CMR).

Methods: Studies were included that reported LV echocardiographic (2DE, CE-2DE, 3DE) and/or MDCT measurements compared to CMR. Only modern CMR (SSFP sequences) was considered. Studies involving small sample size (<10 patients) and unusual cardiac geometry (ie, congenital heart diseases) were excluded. We evaluated LV end-diastolic volume (LVEDV), endsystolic volume (LVESV) and ejection fraction (LVEF). **Results:** 1604 articles were initially considered: 65 studies were included (total of 4032 scans (echo, CT, MRI) performed in 2888 patients). Compared to CMR, significant biased underestimation of LV volumes with 2DE was seen (LVEDV-33.30 mL, LVESV -16.20 mL, p<0.0001). This difference was reduced but remained significant with CE-2DE (LVEDV -18.05, p<0.0001) and 3DE (LVEDV -14.41, p<0.001), while MDCT values were similar to CMR (LVEDV -1.20, p=0.43; LVESV -0.13, p=0.91). However, excellent agreement for echocardiographic LVEF evaluation (2DE LVEF 0.78-1.01%, p=0.37) was observed, especially with 3DE (LVEF 0.14%, p=0.88).

Conclusions: Comparing imaging modalities to CMR as reference standard, 3DE had the highest accuracy in LVEF estimation: 2DE and 3DE-derived LV volumes were significantly underestimated. Newer generation CT showed excellent accuracy for LV volumes.

INTRODUCTION

In the modern era of cardiovascular multimodality imaging, accurate assessment of

KEY QUESTIONS

What is already known about this subject?

Anecdotally, clinicians understand that different imaging methods give different results. For example, echo is known to underestimate LV volumes compared with MRI and these differences are ameliorated with the addition of contrast or 3D echo.


What does this study add?

This study compares all imaging modalities to provide an overall picture of the differences that might be anticipated. Previous studies have evaluated and presented the bias (in percentage units) between echo and MRI, but not the actual values. A unique feature of this meta-analysis is that bias is presented in terms of millilitres (for volumes) and percentage points for ejection fraction; values that translate into clinical practice easily.

How might this impact on clinical practice?

Increasingly, multi-modality imaging is being used to determine left ventricular volumes and ejection fraction. Since these measurements are essential components of clinical management, understanding the anticipated differences that may arise due to different imaging techniques alone, and differentiating these from potential clinical changes, is a key component of clinical management.

left ventricular (LV) function is of paramount importance: LV volumes and ejection fraction (LVEF) are crucial parameters in clinical decision-making, diagnosis and outcome and are included in the main guidelines and trials.^{1–5} The absolute LV parameters, derived from imaging, and their variation over time, are used to guide surgical timing, device implantation and medical therapy introduction.¹² Although several imaging methods are widely available for LV quantification, cardiac MR (CMR) is considered the most accurate modality and is recognised as the gold standard.^b Nevertheless, non-contrast two-dimensional echocardiography (2DE) is still the most



► Additional material is available. To view please visit the journal online (http://dx. doi.org/10.1136/openhrt-2015-000388).

MR and SA were equal contributors to this manuscript and are co-first authors. This author, Dr Whalley, takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

Received 15 December 2015 Revised 9 March 2016 Accepted 15 March 2016



For numbered affiliations see end of article.

Correspondence to

Dr Gillian A Whalley; gillianwhalleyphd@gmail.com



1

widespread method used in clinical practice, mainly due to feasibility, wide distribution and rapid acquisition.⁷ However, 2DE has several intrinsic weaknesses, it is: user-dependent; affected by geometrical assumptions; often subject to foreshortening and limited by poor endocardial definition. By reducing these limitations, three-dimensional echocardiography (3DE) has been reported as a more reproducible and accurate modality for LV volume assessment.^{8–10} In addition, multidetector CT (MDCT) is increasingly available for its clinical applications and as a possible alternative in those patients for whom echocardiography may be unreliable or CMR contraindicated.¹¹ In the past few years, the development of newer MDCT generation scanners has significantly lowered radiation exposure, which is gradually leading to increased adoption.¹² ¹³

However, the use of resource-consuming modalities requires evidence of additive impact on clinical management. It is still not clear if the quantitative advantages of these newer modalities have clinical




Figure 1 Study selection for inclusion.

Open Heart: first published as 10.1136/openhrt-2015-000388 on 27 April 2016. Downloaded from https://openheart.bmj.com on 14 June 2025 by gues:

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Table 1 Inclue	ded studies			
	Publication	Number of		Modalities compared
First author*	year	patients	Population	to MRI
Hundley	1998	35	Patients referred for evaluation of LV function	2D-echo (non-contrast),
Í				2D-echo (contrast)
Schmidt	1999	25	4 normal volunteers; 21 cardiac patients	3D-echo (non-contrast)
Chuang	2000	35	10 healthy adult volunteers; 25 patients with dilated	2D-echo (non-contrast),
			cardiomyopathy	3D-echo (non-contrast)
Qin	2000	16	Patients with normal LV	2D-echo (non-contrast),
				3D-echo (non-contrast)
Chuang	2001	24	12 obese/overweight patients and 12 lean patients	2D-echo (non-contrast),
				3D-echo (non-contrast)
Schalla	2001	34	Cardiac patients	2D-echo (non-contrast)
Mannaerts	2003	17	7 healthy volunteers and 20 patients with: hypertrophic	3D-echo (non-contrast)
Zaidan	0000	4.5	cardiomyopathy, aortic or mitral regurgitation, or AMI	
Zeidan	2003	15	Healthy volunteers	3D-echo (non-contrast)
Jenkins	2004	50	Patients referred to the echo laboratory	2D-echo (non-contrast),
Malm	2004	87	Patients referred to the cardiology department	3D-echo (non-contrast) 2D-echo (non-contrast),
IVIAIIII	2004	07	I allents referred to the cardiology department	2D-echo (contrast)
Caiani	2005	46	Patients with normal LV function	2D-echo (non-contrast),
Calam	2000	-10		3D-echo (non-contrast)
Corsi	2005	16	Normal volunteers and patients with CAD, dilated	3D-echo (non-contrast)
00101	2000	10	cardiomyopathy, valvular disease	
Lim	2005	36	Stable patients with post-AMI	2D-echo (non-contrast),
				2D-echo (contrast)
Wang	2005	11	Patients with chronic CAD	2D-echo (non-contrast)
Chan	2006	30	Patients with previous AMI with altered shape and	3D-echo (non-contrast)
			wall-motion abnormalities	````
Dewey	2006	30	Patients with suspected CAD	2D-echo (non-contrast)
Jenkins	2006	110	Patients referred to the echo laboratory for	2D-echo (non-contrast),
			measurement of LV volumes and EF	3D-echo (non-contrast)
Krenning	2006	15	Male patients with a history of AMI and various degrees	3D-echo (non-contrast)
			of wall-motion abnormalities	
Liew	2006	32	Outpatient cardiac clinic patients with known CAD	2D-echo (non-contrast),
				MDCT 64-slice
Malm	2006	50	Patients submitted to echocardiography were enrolled	2D-echo (non-contrast),
Nilaud	0000	70	OF actions with continuous and OF with contin	2D-echo (nontrast)
Nigri	2006	70	35 patients with aortic stenosis and 35 with aortic	2D-echo (non-contrast)
Nilcitio	0000	64	regurgitation with surgical indication	2D cobo (non contract)
Nikitin	2006	64	40 cardiac patients with LVEF <45%, 14 with EF >45% and 10 normal volunteers	3D-echo (non-contrast)
Sugeng	2006	31	Patients referred for clinically indicated CT angiography	3D-echo (non-contrast)
Brodoefel	2000	20	Patients with chronic CAD	Dual source CT 2x32
Demir	2007	20	Patients with known or suspected CAD	2D-echo (non-contrast)
Giakoumis	2007	135	Patients with thalassaemia major attending an	2D-echo (non-contrast)
Charlounno	2007	100	outpatient clinic	
Jenkins	2007	50	Patients with LV dysfunction due to previous AMI	2D-echo (non-contrast),
			and a state of the	3D-echo (non-contrast)
Jenkins	2007	30	Patients referred to the echo laboratory for	2D-echo (non-contrast),
			measurement of LV volumes and EF	3D-echo (non-contrast)
Krenning	2007	39	Patients referred for routine evaluation of cardiac	3D-echo (non-contrast)
			function after AMI	
Qi	2007	58	44 patients with various cardiac disorders referred for	3D-echo (non-contrast)
			clinical MRI studies and 14 normal patients	
Schlosser	2007	21	Patients referred for CTCA	MDCT 64-slice
Soliman	2007	53	Patients with a cardiomyopathy and adequate 2D image	3D-echo (non-contrast)
			quality	D 07.00
Bastarrika	2008	12	Patients heart transplant recipients	Dual source CT 32×2
Busch	2008	15	Mixed population of patients	Dual source CT 32×2
				Continued

Table 1 Contin				
First author*	Publication year	Number of patients	Population	Modalities compared to MRI
Chukwu	2008	69	35 with normal LV systolic function and 34 with AMI and depressed LV function	2D-echo (non-contrast), 3D-echo (non-contrast)
Leonardi	2008	24	Patients with thalassaemia	2D-echo (non-contrast)
Mor-Avi	2008	92	Patients referred for CMR evaluation of LV size and	3D-echo (non-contrast)
			function	````
Pouleur	2008	83	20 volunteers and 63 patients with heart disease including aortic valve disease, severe mitral regurgitation and previous AMI	3D-echo (non-contrast)
Puesken	2008	28	Patients with known/suspected CAD	MDCT 64-slice
Rutten	2008	78	Mild to moderate patients with COPD with and without heart failure	2D-echo (non-contrast)
Soliman	2008	24	17 patients with impaired LV systolic function due to CAD or idiopathic dilated cardiomyopathy	3D-echo (non-contrast)
Wu	2008	41	Mixed population of patients	MDCT 64-slice
Akram	2009	20	Patients with suspected CAD	MDCT 64-slice
Garcia-Alvarez	2009	65	Patients with first STEMI admitted to a tertiary care hospital and reperfused within 12 h of symptom onset	2D-echo (non-contrast)
Gardner	2009	47	Patients with AMI greater than 6 weeks previously and scheduled for imaging evaluation	2D-echo (non-contrast)
Gjesdal	2009	61	Healthy controls and patients with acute STEMI and treated with PCI	2D-echo (non-contrast)
Guo	2009	51	Patients with mitral regurgitation confirmed by 2D-echo and colour Doppler	2D-echo (non-contrast), MDCT 64-slice
Jenkins	2009	50	Patients with past AMI who underwent echocardiographic assessment of LV volume and function	2D-echo (non-contrast), 2D-echo (contrast), 3D-echo (non-contrast)
Nowosielski	2009	52	Patients with first AMI and PCI	2D-echo (non-contrast)
Sarwar	2009	21	Patients with STEMI	MDCT 64-slice
Abbate	2010	10	Patients with ST-segment elevation AMI	2D-echo (non-contrast)
Claver	2010	43	Unselected patients who underwent CMR; mixed cardiac pathologies	3D-echo (non-contrast)
Palumbo	2010	181	Patients with suspected CAD, indexed volumes	MDCT 64-slice
Whalley	2010	25	Patients with at least moderate MR due to MV prolapse	2D-echo (non-contrast)
De Jonge	2011	26	Patients referred for CTCA	Dual source CT 2×32
Arraiza	2012	25	Patients heart transplant recipients	2D-echo (contrast), dual source CT 2×32
Bak	2012	111	Patients referred for CTCA before valve surgery	2D-echo (non-contrast), dual source 2×32
Brodoefel	2012	20	Patients with known or suspected CAD	Dual source CT 2×32
Coon	2012	18	Patients with CAD, dilated cardiomyopathy, post-AMI, aortic abnormalities and mitral valve disease	3D-echo (non-contrast), 3D-echo (contrast)
Fuchs	2012	53	Patients with previous AMI	MDCT 64-slice
Greupner	2012	36	Patients referred for CTCA	2D-echo (non-contrast), 3D-echo (non-contrast), MDCT 64-slice
Lee	2012	30	Patients who had undergone clinically indicated, routine CCTA studies	MDCT 64-slice
Li	2012	72	Mixed population of cardiac patients	2D-echo (non-contrast)
Maffei	2012	79	Patients referred for CTCA, indexed volumes	MDCT 64-slice
Takx	2012	20	Patients with known or suspected CAD	Dual source CT 2×32
Total	1998-2013	2888	2D Echo (NC): 32 studies/1663 examinations	50 Echo and 20 CT (5
			2D Echo (C): 6 studies/283 examinations	of these included echo
			3D Echo (NC): 27 studies/1137 examinations	and CT)
			3D Echo (C): 3 studies/107 examinations	
			MDCT: 20 studies/842 examinations	

2D, two-dimensional echo; AMI, acute myocardial infarction; C, contrast; CAD, coronary artery disease; CMR, cardiac MR; COPD, chronic obstructive pulmonary disease; CTCA, CT coronary angiography; EF, ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; MDCT, multidetector CT; MV, mitral valve; NC, non-contrast; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.

*See online supplementary file for citations.

Table 2 Summary of meta-regression of differences observed by each method												
		Mean difference co	mpared to	o cardiac MR								
Imaging modality	Year published	LVEDV (mL) (95% Cl)	Overall p value	l ² p value	LVESV (mL) (95% Cl)	Overall p value	l ² p value	LVEF (%) (95% Cl)	Overall p value	l ² p value		
2D-echocardiography Volumes N=1579,	Overall	-33.26 (-43.42 to -20.65)	<0.0001	87% p<0.0001	-16.20 (-21.36 to -11.04)	<0.0001	73% <0.0001	-0.66 (-2.14 to 0.82)	0.38	72% <0.0001		
LVEF N=1683	<2005	-23.23 (-43.86 to -2.59)	0.03	77% p<0.0001	–12.15 (–18.55 to5.75)	0.0002	0% 0.05	–2.11 (–4.48 to 0.26)	0.08	3% 0.40		
	2005–2009	-33.49 (-46.88 to -20.09)	<0.0001	90% p<0.0001	-17.73 (-25.11 to -10.36)	<0.0001	81% <0.0001	-0.26 (-2.32 to 1.81)	0.81	81% <0.0001		
	>2009	-46.46 (-72.27 to -20.65)	0.0004	83% p<0.0001	–18.73 (–29.46 to –8.01)	0.0006	58% 0.05	-1.14 (-3.03 to 0.21)	0.09	0% 0.67		
2D-echocardiography with contrast Volumes and LVEF N=283	Overall*	-18.05 (-6.39 to -9.7)	<0.0001	0% p=0.45	-7.84 (-14.46 to -1.22)	0.02	0% p=0.99	-1.03 (-3.38 to 1.35)	0.39	0% p=0.61		
3D-echocardiography Volumes N=1159,	Overall	–14.16 (–18.66 to –9.66)	<0.0001	23% p=0.12	–6.49 (–9.91 to –3.07)	0.0002	0% p=0.96	0.13 (–0.91 to 1.16)	0.81	0% p=1.00		
LVEF N=1104	<2005	-15.14 (-25.17 to -5.12)	0.003	0% p=0.49	-6.38 (-13.36 to 0.60)	0.07	0% p=0.91	0.25 (-2.09 to 2.59)	0.83	0% p=1.00		
	2005–2009	-13.32 (-18.64 to -8.01)	<0.0001	43% p=0.01	-6.27 (-10.41 to -2.13)	0.003	0% p=0.72	0.02 (-1.20 to 1.23)	0.98	0% p=0.99		
	>2009	–18.95 (–34.54 to –3.36)	0.02	0% p=0.86	-8.77 (-21.00 to 3.47)	0.16	0% p=0.84	0.89 (–2.93 to 4.70)	0.65	9% p=0.33		
Multidetector CT Volumes N=790,	Overall	-1.16 (-4.14 to 1.83)	0.45	0% p=0.90	-0.11 (-2.40 to 2.18)	0.93	0% p=0.96	0.86 (-0.21 to 1.94)	0.12	0% p=0.55		
LVEF N=780	2007–2009	5.21 (–2.13 to 12.54)	0.16	0% p=0.74	2.59 (–1.19 to 6.36)	0.18	0% p=0.93	0.45 (-1.27 to 2.17)	0.51	0% p=0.94		
	>2009	-2.41 (-5.68 to 0.85)	0.15	0% p=0.99	-1.68 (-4.56 to 1.21)	0.25	0% p=0.97	1.13 (-0.25 to 2.50)	0.11	4% p=0.40		

Values are mean (95% CI). *Insufficient number of studies for subgroup analysis. LVEDV, Left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume.

		(Non-con			MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.1.1 <2005										
Hundley 1998	141.4	56.3	35	139.1	62.4	35	3.1%	2.30 [-25.54, 30.14]	1998	
Chuang 2000	180	88	35	200	94	35	2.3%	-20.00 [-62.66, 22.66]	2000	
Qin 2000	106	29	16	142	47	16	3.1%	-36.00 [-63.06, -8.94]	2000	
Chuang 2001 (Lean)	165	64	12	171	69	12	1.9%	-6.00 [-59.25, 47.25]	2001	
Schalla 2001	123	48	34	109	47	34	3.3%	14.00 [-8.58, 36.58]	2001	+
Chuang 2001 (Obese)	190	61	12	221	81	12	1.8%	-31.00 [-88.37, 26.37]	2001	
/alm 2004	126.1	52.2	87	177	60.5	87	3.6%	-50.90 [-67.69, -34.11]	2004	
enkins 2004	112	38	50	160	53	50	3.5%	-48.00 [-66.08, -29.92]	2004	
ubtotal (95% CI)			281			281	22.6%	-23.23 [-43.86, -2.59]		•
Heterogeneity: Tau ² = 61 Fest for overall effect: Z =			= 7 (P <	0.0001);	$l^2 = 77$	%				
1.1.2 2005-2009										
Caiani 2005 (1)	146	65	44	168	70	44	3.0%	-22.00 [-50.23, 6.23]	2005	+
im 2005	111	37	36	131	36	36	3.6%	-20.00 [-36.86, -3.14]		
Dewey 2006	130.4	55.7	30	109.5	57.8	30	3.0%	20.90 [-7.82, 49.62]		+
enkins 2006	110	32	110	180	55	110	3.8%	-70.00 [-81.89, -58.11]		-
ligri 2006 (1)	334.5	157	35	393	141	35	1.4%	-58.50 [-128.41, 11.41]	2006	+
ligri 2006 (2)	193.4	160	35	214	112	35	1.5%	-20.60 [-85.30, 44.10]	2006	
Demir 2007	127.5	42.2	21	91.1	38	21	3.2%	36.40 [12.11, 60.69]	2007	
enkins 2007 (1)	111	29	50	190	54	50	3.6%	-79.00 [-95.99, -62.01]	2007	
enkins 2007 (2)	110	33	30	168	54	30	3.3%	-58.00 [-80.65, -35.35]	2007	
Giakoumis 2007	123.98	26.48	135	138.02	42.98	135	3.9%	-14.04 [-22.56, -5.52]	2007	-
lutten 2008	110	37.5	78	146.1	47.3	78	3.7%	-36.10 [-49.50, -22.70]	2008	
eonardi 2008	156	57	47	172	62	47	3.3%	-16.00 [-40.08, 8.08]	2008	
Chukwu 2008 (Post–MI)	155.8	55.4	34	213.6	65.7	34	3.0%	-57.80 [-86.69, -28.91]	2008	
Chukwu 2008 (Normal)	91.5	20.9	35	130.3	28.3	35	3.8%	-38.80 [-50.46, -27.14]	2008	
Gjesdal 2009	156.9	50.7	61	158.9	52.3	61	3.5%	-2.00 [-20.28, 16.28]	2009	
Gardner 2009	102	42	47	171	62	47	3.4%	-69.00 [-90.41, -47.59]	2009	
Garcia-Alvarez 2009	124.6	35.19	65	152.31	37.58	65	3.8%	-27.71 [-40.23, -15.19]	2009	-
enkins 2009	125	54	50	207	79	50	3.1%	-82.00 [-108.52, -55.48]	2009	
iuo 2009	164.9	63.7	51	188	72.7	51	3.1%	-23.10 [-49.63, 3.43]	2009	
ubtotal (95% CI)			994			994	61.1%	-33.49 [-46.88, -20.09]		◆
leterogeneity: Tau ² = 72 Test for overall effect: Z =			f = 18 (P	< 0.000	01); l ² =	= 90%				
1.1.3 >2009										
Abbate 2010	90	27	10	139	36	10	3.1%	-49.00 [-76.89, -21.11]	2010	
Vhalley 2010	144	36	25	235	48	25	3.3%	-91.00 [-114.52, -67.48]		
Bak 2012	133.7	64.4	111	183.3	94	111	3.4%	-49.60 [-70.80, -28.40]		
Greupner 2012	105.3	53.4	36	131.1	59.4	36	3.2%	-25.80 [-51.89, 0.29]		
i 2012	159.9	54	72	177.1	73.5	72	3.4%	-17.20 [-38.27, 3.87]		
ubtotal (95% CI)			254			254	16.3%	-46.46 [-72.27, -20.65]		◆
leterogeneity: Tau ² = 71 est for overall effect: Z =			= 4 (P <	0.0001);	l ² = 83	%				
Fotal (95% CI)			1529			1529	100.0%	-33.26 [-43.42, -23.11]		•
Heterogeneity: Tau ² = 67 Test for overall effect: Z = Test for subgroup differen	= 6.42 (P < 0).00001)				= 87%				-100 -50 0 50 10 MRI Larger Echo Larger

Figure 2 Left ventricular end-diastolic volume: 2D echo versus CMR. CMR, cardiac MR; 2D, two-dimensional.

significance. The physician should be aware of the difference between modalities when applying the common cut-off for evaluation and follow-up of patients who frequently undergo different types of tests. Moreover, the advances in multi-imaging may have recently been granted higher accuracy due to technical improvements and greater experience. These are the reasons why we sought to assess the difference in absolute values of bias in volumetric and functional LV quantification that may help clinical evaluation. Thus, the aim of our systematic review was to investigate the accuracy of LV assessment by different non-invasive imaging modalities, with a focus on the measurements adopted for patient management.

MATERIALS AND METHODS

The meta-analysis conforms to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.

Search strategy

The authors developed these strategies for database searching: the MEDLINE/PubMed database was searched from January 1995 in consideration of the fact that the steady state free precession (SSFP) MRI technique that is currently used for CMR cine images acquisition was only available in the late 1990s. The literature search was limited to human adults in order to exclude studies involving children with congenital heart disease and consequent abnormal cardiac geometry. Abstracts and articles published in languages other than English were not excluded. A total of 1604 articles published over a period of 19 years were identified for initial review: 1020 and 584 in the echocardiography and CT groups, respectively.

Echocardiographic modalities versus CMR search

The search strategy was determined (by GW and JC) and the first initial literature search carried out (by SA), and an updated version (by MR) was then performed,

	2D-Echo	(Non-con	tract)		MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD		Mean		Total	Weight	IV, Random, 95% CI	Vear	IV, Random, 95% CI
1.2.1 <2005	Mean	30	TOTAL	Weatt	30	Total	weight	IV, Kalidolii, 95% Cl	Tear	
Hundley 1998	79.4	53	35	84.2	61.2	35	2.2%	-4.80 [-31.62, 22.02]	1009	
Chuang 2000	79.4 94	83	35	110	89	35	1.2%	-16.00 [-56.32, 24.32]		
Qin 2000	43	12	16	59	24	16	3.9%			
Chuang 2001 (Lean)	43 91	62	10	59 94	69	10	0.8%	-16.00 [-29.15, -2.85]		
Chuang 2001 (Dese)	91	66	12	113	78	12	0.8%	-3.00 [-55.48, 49.48] -21.00 [-78.81, 36.81]		
Schalla 2001 (Obese)	63	40	34	52	78 41	34	3.0%	11.00 [-8.25, 30.25]		
Jenkins 2004	54	33	50	73	53	50	3.3%	-19.00 [-36.31, -1.69]		
Malm 2004	63	43.8	87	78.7	56.4	87	3.6%	-15.70 [-30.71, -0.69]		
Lim 2005	53	43.8	36	67	33	36	3.9%	-14.00 [-27.52, -0.48]		
Subtotal (95% CI)	22	25	317	07	22	317	22.7%	-12.15 [-18.55, -5.75]	2005	•
Heterogeneity: $Tau^2 = 0.09$	0: $Chi^2 = 7$	30. df = 8	(P = 0.5)	0): $I^2 = 0$	0%					×.
Test for overall effect: $Z =$			(1 = 0.5	0), 1 = 1	070					
	5172 (
1.2.2 2005-2009										
Caiani 2005 (1)	82	60	44	99	69	44	2.2%	-17.00 [-44.02, 10.02]		
Nigri 2006 (1)	183.5	105		235.6	131	35	0.7%	-52.10 [-107.72, 3.52]		
Malm 2004 (1)	69.8	48	50	80.9	69.4	50	2.5%	-11.10 [-34.49, 12.29]		
Dewey 2006	50.5	33.2	30	46	47.5	30	2.8%	4.50 [-16.24, 25.24]		
Nigri 2006 (2)	94.8	92	35	127	102	35	1.0%	-32.20 [-77.71, 13.31]		
Jenkins 2006	59	27	110	93	50	110	4.3%	-34.00 [-44.62, -23.38]		
Jenkins 2007 (1)	63	25	50	99	51	50	3.5%	-36.00 [-51.74, -20.26]		
Giakoumis 2007	41.05	14.59		45.51		135	5.1%	-4.46 [-8.78, -0.14]		7
Jenkins 2007 (2)	60	27	30	87	49	30	2.9%	-27.00 [-47.02, -6.98]		
Demir 2007	59.9	37.6	21	41.8	26.9	21	3.0%	18.10 [-1.67, 37.87]		
Chukwu 2008 (Post-MI)	96.4	51.2	34	141.8	69.2	34	2.0%	-45.40 [-74.33, -16.47]		
Leonardi 2008	72	44	47	79	46	47	3.2%	-7.00 [-25.20, 11.20]		
Chukwu 2008 (Normal)	30	9.7	35	54.5	15.4	35	4.9%	-24.50 [-30.53, -18.47]		T .
Rutten 2008	55.6	34.8	78	70	45.4	78	4.0%	-14.40 [-27.09, -1.71]		
Gjesdal 2009	74.4	40.7	61	70.8	39.3	61	3.8%	3.60 [-10.60, 17.80]		
Guo 2009	74.5	30.2	51	92.9	41.9	51	3.8%	-18.40 [-32.58, -4.22]		
Gardner 2009	53	28	47	88	47	47	3.5%	-35.00 [-50.64, -19.36]		
Garcia-Alvarez 2009	68.34	25.33		74.76		65	4.5%	-6.42 [-15.99, 3.15]		-
Jenkins 2009	73	44	50	117	71	50	2.6%	-44.00 [-67.15, -20.85]	2009	
Subtotal (95% CI)			1008		0.4.2	1008	60.3%	-17.73 [-25.11, -10.36]		•
Heterogeneity: Tau ² = 177 Test for overall effect: Z =			= 18 (P -	< 0.000	01); 1- =	= 81%				
		/								
1.2.3 >2009						2				
Abbate 2010	50	24	10	71	28	10	2.6%	-21.00 [-43.86, 1.86]		
Whalley 2010	54	14	25	85	21	25	4.4%	-31.00 [-40.89, -21.11]		-
Greupner 2012	51.3	43.7	36	65.6	61.9	36	2.4%	-14.30 [-39.05, 10.45]		
Li 2012	71.97	44.74		73.82		72	3.4%	-1.85 [-18.22, 14.52]		
Bak 2012 Subtotal (95% CI)	48.1	37.4	111 254	67.4	49.4	111 254	4.2% 17.0%	-19.30 [-30.83, -7.77] - 18.73 [-29.46, -8.01]	2012	→
Heterogeneity: $Tau^2 = 81$.	15; Chi ² =	9.54, df =	4 (P = 0.0)	05); I ² =	58%			and a second standard		
Test for overall effect: Z =				,, .						
Total (95% CI)			1579			1579	100.0%	-16.20 [-21.36, -11.04]		♦
Heterogeneity: $Tau^2 = 131$	78; Chi ² =	117.95, c	lf = 32 (P	< 0.00	001); I ²	= 73%				-100 -50 0 50 100
Test for overall effect: Z =	6.15 (P < 0	0.00001)								–100 –50 0 50 100 MRI Larger Echo Larger
Test for subgroup differen	ces: Chi ² =	1.74, df =	= 2 (P = 0	.42), I ²	= 0%					wiki Larger Echo Larger

Figure 3 Left ventricular end-systolic volume: 2D echo versus CMR. CMR, cardiac MR; 2D, two-dimensional

using the following search terms: heart OR heart ventricles OR ventric*.mp AND left.mp AND cardiac volume OR heart volume OR cardiac output OR ventricular function OR ventricular dysfunction AND echocardiography OR echo.mp OR echocardiogram*.mp AND MRI OR magnetic resonance spectroscopy OR MRI.mp OR MR scan.mp OR magnetic resonance scan*.mp. The titles and abstracts of all studies identified were initially screened (by SA and MR) and reviewed (by MR and GW).

CT versus CMR search

The initial search for volumetric comparison between CT and CMR was conducted using the following search terms: heart OR cardiac OR ventricular OR ventricle OR cardiovascular AND volume OR volumes OR volumetric OR function OR dysfunction OR cardiac output AND magnetic resonance OR MRI OR MR OR MRI AND CT OR CT OR dual-source OR multi-detector OR MDCT. The titles and abstracts of all studies identified were initially screened (by SA) and reviewed (by MR and GW).

All modalities

A cross-reference process was undertaken (by SA) to search and the studies initially identified in the separate searches and the final papers were reviewed by the other authors (MR and GW). The reference lists were manually searched for potential other studies, and duplicate studies were identified and excluded.

Criteria for study selection

We excluded individual case reports, studies involving a sample size of <10 patients and those that included patients with unusual geometry (eg, congenital heart disease, Takotsubo and hypertrophic cardiomyopathy). Only newer generation CT scanners were included: at

	2D-Echo		,		MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
1.3.1 <2005										
Hundley 1998	47.7	16.9	35	44.7	16.9	35	2.0%	3.00 [-4.92, 10.92]		
Chuang 2000	53	19	35	50	16	35	1.9%	3.00 [-5.23, 11.23]		
Qin 2000	59	7	16	59	8	16	3.0%	0.00 [-5.21, 5.21]		
Schalla 2001	52	15	34	58	17	34	2.1%	-6.00 [-13.62, 1.62]		
Chuang 2001 (Obese)	56	21	12	53	16	12	0.8%	3.00 [-11.94, 17.94]		
Chuang 2001 (Lean)	50	18	12	51	19	12		-1.00 [-15.81, 13.81]		
Jenkins 2004	49	14	50	52	14	50	2.9%	-3.00 [-8.49, 2.49]		
Malm 2004	54	12.5	87	59	14.6	87	3.5%	-5.00 [-9.04, -0.96]	2004	
Subtotal (95% CI)			281			281	17.1%	-2.11 [-4.48, 0.26]		-
Heterogeneity: Tau ² = 0.4 Test for overall effect: Z =			(P = 0.4)	0); I ² =	3%					
1.3.2 2005-2009										
Lim 2005	53	12	36	51	14	36	2.7%	2.00 [-4.02, 8.02]		-+
Caiani 2005 (1)	49	18	44	46	19	44	2.1%	3.00 [-4.73, 10.73]	2005	— —
Hoffmann 2005	50.9	15.3	55	54.1	18.3	55	0.0%	-3.20 [-9.50, 3.10]	2005	
Nigri 2006 (1)	50	10	35	50	10	35	3.2%	0.00 [-4.69, 4.69]	2006	-+
Dewey 2006	61.5	11.6	30	63.8	14.3	30	2.5%	-2.30 [-8.89, 4.29]	2006	
Jenkins 2006	48	12	110	50	13	110	3.8%	-2.00 [-5.31, 1.31]	2006	-+
Nigri 2006 (2)	58	10	35	59	10	35	3.2%	-1.00 [-5.69, 3.69]	2006	
Demir 2007	55.7	16.4	21	56.4	15.7	21	1.6%	-0.70 [-10.41, 9.01]	2007	
Giakoumis 2007	66.87	6.39	135	67.09	7.88	135	4.5%	-0.22 [-1.93, 1.49]	2007	-+
Jenkins 2007 (2)	46	11	30	49	13	30	2.6%	-3.00 [-9.09, 3.09]	2007	
Jenkins 2007 (1)	45	10	50	50	12	50	3.4%	-5.00 [-9.33, -0.67]	2007	
Leonardi 2008	55	12	47	56	11	47	3.2%	-1.00 [-5.65, 3.65]	2008	
Rutten 2008	52.4	11.2	78	54.8	12.3	78	3.7%	-2.40 [-6.09, 1.29]	2008	+
Chukwu 2008 (Normal)	67.5	6.6	35	58.4	6.2	35	4.0%	9.10 [6.10, 12.10]	2008	
Chukwu 2008 (Post–MI)	42	17.4	34	37.4	15.9	34	2.0%	4.60 [-3.32, 12.52]	2008	
Gardner 2009	47	11	47	51	11	47	3.3%	-4.00 [-8.45, 0.45]	2009	
Guo 2009	54.2	9.5	51	50.5	9.8	51	3.6%	3.70 [-0.05, 7.45]	2009	——
Jenkins 2009	43	10	50	47	10	50	3.6%	-4.00 [-7.92, -0.08]	2009	
Garcia-Alvarez 2009	46.41	9.24	65	51.99	11.68	65	3.7%	-5.58 [-9.20, -1.96]	2009	
Gjesdal 2009	49.1	9.9	61	57.1	12.2	61	3.6%	-8.00 [-11.94, -4.06]	2009	
Nowosielski 2009 (BL)	51.2	8.1	52	44.2	11.6	52	3.6%	7.00 [3.15, 10.85]	2009	——
Nowosielski 2009 (FU) Subtotal (95% CI)	54.5	8.3	52 1098	49.2	11.1	52 1098	3.6% 67.5%	5.30 [1.53, 9.07] - 0.26 [-2.32, 1.81]	2009	↓
Heterogeneity: $Tau^2 = 17$.			= 20 (P ·	< 0.000	01); I ² =	= 81%				
Test for overall effect: Z =	0.24 (P = 0	.81)								
1.3.3 >2009	62	c		<i>c</i> ·		25	4 10/		2010	
Whalley 2010	62	6	25	64	4	25	4.1%	-2.00 [-4.83, 0.83]		
Abbate 2010	49	12	10	50	11	10	1.5%	-1.00 [-11.09, 9.09]		
Bak 2012	65.5	8.6	111	66	9.5	111	4.2%	-0.50 [-2.88, 1.88]		
Greupner 2012	56.3	14.7	36	55.6	16	36	2.3%	0.70 [-6.40, 7.80]		
Li 2012	57.49	12.41		61.43	14.34	72 254	3.4%	-3.94 [-8.32, 0.44]	2012	
Subtotal (95% CI)	a a 2 a		254		00/	254	15.4%	-1.41 [-3.03, 0.21]		
Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =			(P = 0.6	7); ² =	0%					
Total (95% CI)			1633			1633	100.0%	-0.66 [-2.14, 0.82]		•
Heterogeneity: $Tau^2 = 11$. Test for overall effect: $Z =$ Test for subgroup differen	0.87 (P = 0)	.38)				= 72%				–20 –10 0 10 MRI Higher Echo Higher

Figure 4 Left ventricular ejection fraction: 2D echo versus CMR. CMR, cardiac MR; 2D, two-dimensional

least MDCT 64 slice or dual source CT (DSCT) 2×32 slice for their improved temporal resolution and Z-axis coverage. Following these exclusions, 351 echocardiog-raphy and 93 MDCT articles were available for full review.

Data extraction

Data were extracted and recorded in an electronic database including: number of patients who received echocardiography, CT and MRI; and group mean values and SDs for LV end-diastolic volume (LVEDV), LV end-




Figure 5 Left ventricular end-diastolic volume: 2D echo with contrast versus CMR. CMR, cardiac MR; 2D, two-dimensional.




Figure 6 Left ventricular end-systolic volume: 2D echo with contrast versus CMR. CMR, cardiac MR; 2D, two-dimensional.

systolic volume (LVESV) and LVEF. Where the article content was insufficient, the corresponding or senior authors of the studies were contacted for further information. In the case of potential duplicate publications, clarification was sought from the authors and the largest single published data set was used for the systematic review. At the same time, additional references to either published or unpublished studies were sought.

Statistical analysis

Analyses of the collected data were performed using the Cochrane Collaboration Program Review Manager V.5.2 software. Data were collected from individual studies and weighted according to number of patients in the sample. Mean LVEDV, LVESV, LVEF and correspondent SD were used to calculate a pool estimate of the three parameters. The χ^2 test was adopted to determine heterogeneity. Study variation due to heterogeneity was evaluated with inconsistency (I^2). I^2 values >30% were considered as significant variation. Funnel plots were used to evaluate study-level and publication bias. Absolute pooled mean values and CIs (95%) were tested with the fixed effect model of Mantel-Hanszel in case of homogeneity, and with the random effect model of DerSimonian-Laird if heterogeneity was reported. A p value <0.05 was considered significant.

RESULTS

We identified 1020 echocardiography and 584 CT publications. Of these, 351 and 93 were considered potentially eligible. Two additional studies were found from a cross-reference check of relevant studies. After screening the full-text articles for relevance and eligibility, 50 articles comparing echocardiography to MRI and 20 studies comparing CT to MRI remained (figure 1). Owing to the overlap of five studies that analysed both echocardiography and CT versus MRI, the total number of studies included was 65 (table 1, reference list is available as online supplementary data). All the articles or abstracts were published in peer-review journals.

2D Echocardiography and CMR comparison

Overall, 2888 patients (4032 scans) were included. Compared to CMR, there were significant differences in LVEDV and LVESV, with observed high levels of heterogeneity (87%) and bias from funnel plots (table 2, figures 2 and 3). Although a significant bias was not detected for LVEF (mean difference: -0.78% (95% CI -2.24% to -0.68)), similar high levels of heterogeneity (72%) and bias were observed (table 2 and figure 4). This heterogeneity renders the calculated mean difference unreliable, but it does highlight a clinically relevant underestimation of the volumes and supports the overall findings that these methods are not interchangeable.

2D echocardiography with contrast and CMR comparison

When contrast was added to 2DE, significant differences in LVEDV and LVESV remained: CE-2DE underestimated both volume measurements (table 2, figures 5 and 6) but LVEF was similar compared to CMR and neither heterogeneity nor bias was seen (table 2 and figure 7).





Figure 7 Left ventricular ejection fraction: 2D echo with contrast versus CMR. CMR, cardiac MR; 2D, two-dimensional.

	2D-Echo	(Non-cont	ract)		MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean		Total	Weight	IV, Fixed, 95% CI	Vear	IV, Fixed, 95% CI
3.1.1 <2005	Mcun	50	Total	Mcun	50	Total	weight	10, 11, 20, 35% CI	rear	10, 11, 20, 55% 21
Nosir 1999	182	76	40	181	76	40	1.8%	1.00 [-32.31, 34.31]	1000	
Schmidt 1999	149	66	25	181	76	25	1.8%	-33.00 [-72.46, 6.46]		
Nosir 2000	217	95	23	218	98	23	0.6%	-1.00 [-59.38, 57.38]		
Qin 2000	120	37	16	142	98 47	16	2.4%	-22.00 [-51.31, 7.31]		
	120	91	35	142	91	35		the second state of the second state of the second state		
Chuang 2000 Chuang 2001 (Laan)		65		198	69	12	1.1% 0.7%	-1.00 [-43.64, 41.64]		
Chuang 2001 (Lean)	167		12					-4.00 [-57.63, 49.63]		
Chuang 2001 (Obese)	217	82	12	221	81	12	0.5%	-4.00 [-69.21, 61.21]		
Mannaerts 2003	100.6	26.5	17	140.5	40.3	17		-39.90 [-62.83, -16.97]		
Zeidan 2003	108	32	15	114	36	15	3.4%	-6.00 [-30.38, 18.38]		
Jenkins 2004 Subtotal (95% CI)	153	55	50 243	160	53	50 243	4.5%	-7.00 [-28.17, 14.17] -15.14 [-25.17, -5.12]	2004	
	1 15 0 (5	0 10 12				243	20.1%	-13.14 [-23.17, -3.12]		•
Heterogeneity: $Chi^2 = 8.4$			= 0%							
Test for overall effect: Z =	2.96 (P = 0)	.003)								
3.1.2 2005-2009										
Caiani 2005 (1)	162	68	44	168	70	44	2.4%	-6.00 [-34.84, 22.84]	2005	
Corsi 2005	143	42	16	140	41	16	2.4%	3.00 [-25.76, 31.76]	2005	
Krenning 2006	177	40	15	186	41	15	2.4%	-9.00 [-37.99, 19.99]	2006	
Chan 2006	169	61	30	179	56	30	2.3%	-10.00 [-39.63, 19.63]		
Nikitin 2006	202	74	64	195	72	64	3.2%	7.00 [-18.30, 32.30]		
Sugeng 2006	207	104	31	212	106	31	0.7%	-5.00 [-57.27, 47.27]		
Jenkins 2006	164	49	110	180	55	110	10.7%	-16.00 [-29.77, -2.23]		
Soliman 2007	165	50	53	175	51	53	5.5%	-10.00 [-29.23, 9.23]		
Jenkins 2007 (2)	155	37	30	168	54	30	3.7%	-13.00 [-36.42, 10.42]		
Qi 2007	117.36	53.24	58	139.45	59.18	58	4.8%	-22.09 [-42.58, -1.60]		
Jenkins 2007 (1)	173	43	50	190	54	50	5.5%	-17.00 [-36.13, 2.13]		
Krenning 2007	198	60	39	218	70	39	2.4%	-20.00 [-48.94, 8.94]		
Soliman 2008	213	63	24	221	54	24	1.8%	-8.00 [-41.20, 25.20]		
Mor-Avi 2008	160	70	92	227	100	92		-67.00 [-91.94, -42.06]		
Chukwu 2008 (Post-MI)	208.8	68.2	34	213.6	65.7	34	2.0%	-4.80 [-36.63, 27.03]		
Chukwu 2008 (Normal)	131.4	28.9	35	130.3	28.3	35	11.3%	1.10 [-12.30, 14.50]		+
Pouleur 2008	167	68	83	187	70	83	4.6%	-20.00 [-41.00, 1.00]		
Jenkins 2009	177	64	50	207	79	50	2.5%	-30.00 [-58.18, -1.82]		
Subtotal (95% CI)			858			858	71.6%	-13.32 [-18.64, -8.01]		•
Heterogeneity: $Chi^2 = 29.3$	85, df = 17	(P = 0.03);	$I^2 = 43\%$	5						
Test for overall effect: Z =	4.91 (P < 0	.00001)								
3.1.3 >2009										
Claver 2010	132.4	49.8	43	154.5	51.7	43	4.4%	-22.10 [-43.56, -0.64]	2010	
Coon 2012	202	62	18	211	63	18	1.2%	-9.00 [-49.83, 31.83]		
Greupner 2012 Subtotal (95% CI)	112.8	58.7	36 97	131.1	59.4	36 97	2.7% 8.3%	-18.30 [-45.58, 8.98] -18.95 [-34.54, -3.36]	2012	•
Heterogeneity: $Chi^2 = 0.3$	1, df = 2 (P =	= 0.86); I ²	= 0%							
Test for overall effect: Z =										
Total (95% CI)			1198			1198	100.0%	-14.16 [-18.66, -9.66]		•
Heterogeneity: $Chi^2 = 39.0$ Test for overall effect: Z =	to a second a second of the second of the			5						-100 -50 0 50 100 MRI Larger Echo Larger
Test for subgroup differer	nces: Chi ² =	0.49, df =	2 (P = 0	.78), I ² =	0%					WINI Larger ECHO Larger



3D echocardiography and CMR comparison

Using 3DE further reduced the absolute size of the bias, but significant underestimation remained for LVEDV and LVESV (table 2, figures 8 and 9). However LVEF was similar and neither heterogeneity nor bias was seen (table 2 and figure 10).

CT and CMR comparison

Of the 20 CT studies that were included, 12 adopted a 64-slice MDCT, while the remaining eight employed a dual source technology (2×32 slices). No differences were observed between CT and CMR for any volume or LVEF measure, and heterogeneity was uniformly absent; also, the funnel plots revealed no bias (table 2 and figures 11–13).

When considered over time, no significant differences in the summary statistics were seen for any measure or modality with widely overlapping CIs, suggesting no obvious impact of improved technology over this time period.

DISCUSSION

To the best of our knowledge, this is the first meta-analysis to evaluate all of the most commonly available non-invasive modalities for LV volume and LVEF quantification over nearly two decades of literature search. Our data show that 3DE provides the highest accuracy for LVEF quantification, while newer generation CT is the most precise method for assessment of LV volumes, when compared to CMR. Moreover, 2DE (non-contrast and contrast-enhanced) significantly underestimates LV volumes.

Despite the clinical importance of LV volumetric and functional quantification, no consensus remains on the best modality for assessment. Although it is acknowledged that bias may occur, the absolute differences in LV volumes and LVEF by various imaging methods are largely unquantifiable. It is important to determine, and quantify, if there is a significant absolute bias between modalities especially for follow-up that nowadays is increasingly performed with different types of

	3D-Echo (Non-cont	rast)		MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD		Mean		Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
3.2.1 <2005			Total	mean		. otai	neight		. eu	,
Nosir 1999	122	77	40	120	76	40	1.0%	2.00 [-31.53, 35.53]	1999	
Schmidt 1999	70	35	25	70	43	25	2.5%	0.00 [-21.73, 21.73]		
Qin 2000	50	17	16	59	24	16	5.6%	-9.00 [-23.41, 5.41]		
Chuang 2000	104	90	35	105	91	35	0.6%	-1.00 [-43.40, 41.40]		
Nosir 2000	155	99	21	154	98	21	0.3%	1.00 [-58.58, 60.58]		
Chuang 2001 (Obese)	112	80	12	113	78	12	0.3%	-1.00 [-64.22, 62.22]		
Chuang 2001 (Lean)	93	65	12	94	69	12	0.4%	-1.00 [-54.63, 52.63]		
Zeidan 2003	43	18	15	47	21	15	6.0%	-4.00 [-18.00, 10.00]		_
Mannaerts 2003	40.8	20.7	17	60.6	28.5	17	4.2%	-19.80 [-36.54, -3.06]		
enkins 2004	74	47	50	73	53	50	3.0%	1.00 [-18.63, 20.63]		
Subtotal (95% CI)	74	47	243	15	22	243	24.0%	-6.38 [-13.36, 0.60]	2004	
Heterogeneity: $Chi^2 = 4.0$	1 df = 0 (P =	- 0 01)· 12				215	2 110/0	0150 [15150; 0100]		•
Test for overall effect: Z =			- 0%							
8.2.2 2005-2009										
Corsi 2005	67	36	16	64	34	16	2.0%	3.00 [-21.26, 27.26]		
Caiani 2005 (1)	96	64	44	99	69	44	1.5%	-3.00 [-30.81, 24.81]		
ugeng 2006	121	85	31	126	96	31	0.6%	-5.00 [-50.14, 40.14]	2006	
renning 2006	96	25	15	99	28	15	3.2%	-3.00 [-22.00, 16.00]	2006	
likitin 2006	121	66	64	117	68	64	2.2%	4.00 [-19.22, 27.22]	2006	
han 2006	95	48	30	96	54	30	1.7%	-1.00 [-26.85, 24.85]	2006	<u> </u>
enkins 2006	83	39	110	93	50	110	8.3%	-10.00 [-21.85, 1.85]	2006	
enkins 2007 (2)	80	33	30	87	49	30	2.6%	-7.00 [-28.14, 14.14]	2007	
enkins 2007 (1)	91	38	50	99	51	50	3.8%	-8.00 [-25.63, 9.63]	2007	
Qi 2007	64.3	46.8	58	79.75	57.26	58	3.2%	-15.45 [-34.48, 3.58]	2007	
Crenning 2007	116	58	39	125	69	39	1.5%	-9.00 [-37.29, 19.29]	2007	
Soliman 2007	69	48	53	74	51	53	3.3%	-5.00 [-23.86, 13.86]	2007	
Soliman 2008	122	69	24	127	61	24	0.9%	-5.00 [-41.85, 31.85]	2008	
ouleur 2008	88	56	83	101	65	83	3.4%	-13.00 [-31.46, 5.46]	2008	
Chukwu 2008 (Normal)	52.5	13.6	35	54.5	15.4	35	25.2%	-2.00 [-8.81, 4.81]	2008	+
Chukwu 2008 (Post–MI)	137.5	67.4	34	141.8	69.2	34	1.1%	-4.30 [-36.77, 28.17]	2008	
lor-Avi 2008	103	71	92	144	99	92	1.9%	-41.00 [-65.89, -16.11]	2008	
enkins 2009	100	57	50	117	71	50	1.8%	-17.00 [-42.24, 8.24]	2009	
ubtotal (95% CI)			858			858	68.2%	-6.27 [-10.41, -2.13]		♦
leterogeneity: Chi ² = 13. est for overall effect: Z =			$I^2 = 0\%$							
.2.3 >2009										
laver 2010	60.4	32.2	43	66.5	39.3	43	5.1%	-6.10 [-21.29, 9.09]	2010	-+
Greupner 2012	52.6	48.4	36	65.6	61.9	36	1.8%	-13.00 [-38.67, 12.67]	2012	
Coon 2012 Subtotal (95% CI)	122	48	18 97	137	58	18 97	1.0% 7.8%	-15.00 [-49.78, 19.78] -8.77 [-21.00, 3.47]	2012	•
eterogeneity: $Chi^2 = 0.3$			= 0%							~
Test for overall effect: Z =	1.40 (P = 0.	16)								
otal (95% CI)			1198			1198	100.0%	-6.49 [-9.91, -3.07]		•
Heterogeneity: $Chi^2 = 17$.			$I^2 = 0\%$							-100 -50 0 50 10
<pre>Fest for overall effect: Z = Fest for subgroup differer</pre>			2 (P = 0	.93), I²	= 0%					MRI Larger Echo Larger

Figure 9 Left ventricular end-systolic volume: 3D echo versus CMR. CMR, cardiac MR; 3D, three-dimensional.

tests. This may impact considerably on clinical management of various cardiac conditions, particularly in patients with borderline LV volumes and LVEF values. A better comprehension of their parameter variability between tests may enhance therapeutic decisions. Small studies evaluating echocardiography and CT in comparison to CMR demonstrated controversial results. Greupner *et al*¹⁴ reported the CT superiority in assessing all three global LV parameters compared to 2DE, 3DE and ventriculography when CMR values are used as reference standard. Interestingly, 3DE did not perform better than 2DE, in contrast with previous reports and prior meta-analyses.⁸ ⁹ ¹⁵ In our study, despite the underestimation of LV volume by 3DE, almost no difference was seen for LVEF when compared to CMR. The underestimation of volumes observed is concordant with the results of two previous meta-analyses⁸ ⁹ that evaluated the sources of bias and limits of agreement affecting 3DE. When LV function was considered, there was no difference in bias between 2DE and 3DE, with

only a modest difference in variance.⁸ In contrast to these previous studies, we decided to focus on the absolute difference between LV parameters and to exclude the cardiac conditions that markedly alter geometric shape. In fact, the inclusion of major anatomical ventricular alterations (eg, congenital and primary cardiomyopathies) may have influenced prior results, especially when 2DE geometrically based assessments were compared. These former systematic reviews included congenital heart abnormalities in which the global ventricular structure was markedly changed. This may have resulted in an unfair comparison for 2DE versus 3D modalities considering that congenital diseases represent a significantly reduced proportion of most common everyday clinical practice. Our data confirm that, even excluding limited cardiac diseases in which echocardiography has known limitations, 2DE and 3DE significantly underestimate LV volumes. Although 3DE relies on fewer geometrical assumptions than 2DE and approximately halves the absolute bias of Open Heart: first published as 10.1136/openhrt-2015-000388 on 27 April 2016. Downloaded from https://openheart.bmj.com on 14 June 2025 by gues:

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

		(Non-cont			MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
3.3.1 <2005										
Nosir 1999	38	18	40	39	18	40	1.7%	-1.00 [-8.89, 6.89]	1999	
Chuang 2000	52	17	35	52	17	35	1.7%	0.00 [-7.96, 7.96]	2000	
Qin 2000	59	6	16	59	8	16	4.5%	0.00 [-4.90, 4.90]	2000	
Nosir 2000	34	17.9	21	34.7	17.9	21	0.9%	-0.70 [-11.53, 10.13]	2000	
Chuang 2001 (Obese)	52	17	12	53	16	12	0.6%	-1.00 [-14.21, 12.21]	2001	
Chuang 2001 (Lean)	50	18	12	51	19	12	0.5%	-1.00 [-15.81, 13.81]	2001	
Zeidan 2003	62	6	15	60	8	15	4.2%	2.00 [-3.06, 7.06]	2003	
Mannaerts 2003	60.3	12.2	17	57.4	13.6	17	1.4%	2.90 [-5.78, 11.58]	2003	
enkins 2004	51	12	50	52	14	50	4.1%	-1.00 [-6.11, 4.11]	2004	
Subtotal (95% CI)			218			218	19.6%	0.25 [-2.09, 2.59]		•
Heterogeneity: $Chi^2 = 1.2$	5, $df = 8 (P)$	$= 1.00); I^2$	= 0%							
Test for overall effect: Z =	= 0.21 (P = 0)	.83)								
3.3.2 2005-2009										
Corsi 2005	55	13	16	56	12	16	1.4%	-1.00 [-9.67, 7.67]	2005	
Caiani 2005 (1)	45	17	44	46	19	44	1.9%	-1.00 [-8.53, 6.53]	2005	
Nikitin 2006	43	15	64	44	16	64	3.7%	-1.00 [-6.37, 4.37]	2006	
enkins 2006	51	10	110	50	13	110	11.4%	1.00 [-2.06, 4.06]	2006	
Sugeng 2006	47	15	31	46	16	31	1.8%	1.00 [-6.72, 8.72]	2006	
enkins 2007 (1)	49	10	50	50	12	50	5.7%	-1.00 [-5.33, 3.33]	2007	
Krenning 2007	43	13	39	45	5	39	5.6%	-2.00 [-6.37, 2.37]	2007	
enkins 2007 (2)	49	11	30	49	13	30	2.9%	0.00 [-6.09, 6.09]	2007	-+
Qi 2007	48.99	12.99	58	47.32	16.86	58	3.6%	1.67 [-3.81, 7.15]	2007	
Soliman 2007	61	18	53	61	17	53	2.4%	0.00 [-6.67, 6.67]	2007	
Chukwu 2008 (Post–MI)	37.5	14.4	34	37.4	15.9	34	2.1%	0.10 [-7.11, 7.31]	2008	
Pouleur 2008	50	14	83	50	16	83	5.1%	0.00 [-4.57, 4.57]	2008	
Mor-Avi 2008	39	15	92	42	17	92	5.0%	-3.00 [-7.63, 1.63]	2008	
Chukwu 2008 (Normal)	60.1	6	35	58.4	6.2	35	13.1%	1.70 [-1.16, 4.56]	2008	+
Soliman 2008	47	15	24	48	14	24	1.6%	-1.00 [-9.21, 7.21]	2008	
enkins 2009	47	12	50	47	10	50	5.7%	0.00 [-4.33, 4.33]	2009	
Subtotal (95% CI)			813			813	73.0%	0.02 [-1.20, 1.23]		♦
Heterogeneity: $Chi^2 = 5.1$	2, $df = 15$ (F	P = 0.99; 1	$^{2} = 0\%$							
Test for overall effect: Z =	0.03 (P = 0	.98)								
3.3.3 >2009										
Claver 2010	56.7	12.8	43	59	14.3	43	3.3%	-2.30 [-8.04, 3.44]	2010	
Coon 2012	41	10	18	37	11	18	2.3%	4.00 [-2.87, 10.87]	2012	
Greupner 2012	58.3	17.2	36	55.6	16	36	1.8%	2.70 [-4.97, 10.37]	2012	
Subtotal (95% CI)			97			97	7.4%	0.89 [-2.93, 4.70]		
Heterogeneity: $Chi^2 = 2.1$	9, df = 2 (P	= 0.33); I ²	= 9%							
Test for overall effect: Z =	= 0.45 (P = 0)	.65)								
Total (95% CI)			1128			1128	100.0%	0.13 [-0.91, 1.16]		♦
Heterogeneity: $Chi^2 = 8.7$	5, df = 27 (F	$P = 1.00); I^2$	$^{2} = 0\%$							+ + + + + + + + + + + + + + + + + + + +
Test for overall effect: Z =	= 0.24 (P = 0	.81)								-20 -10 0 10 MRI Larger Echo Larger
est for subgroup differer	ncos: Chi2 -	0.20 df -	2(P - 0)	Q1) 1 ²	- 0%					WINI Larger ECHO Larger

Figure 10 Left ventricular ejection fraction: 3D echo versus CMR. CMR, cardiac MR; 3D, three-dimensional.

underestimation, it still performs worse than CT, compared with CMR. This is probably due to the reduced spatial resolution and consequent lack of precision in distinguishing myocardial trabeculations and endocardial borders.^{9 16 17}

The highest spatial resolution of CT and its similar 3D reconstruction method to CMR may explain the perfect agreement observed in quantification of volumes. Our results are complementary to two previous systemic reviews comparing CT and CMR, one on older and one on newer generation scanners.¹⁸¹⁹ These have shown a good agreement for LVEF, but no analysis of LV volumes bias compared to CMR was performed. However, our data suggest that functional evaluation is not as good as echocardiography when compared to CMR. Although CT has the disadvantages of risk radiation and iodinated contrast exposure, it remains a useful method for second-level cardiac anatomical evaluation in those patients with contraindications to MRI (eg, implanted devices, claustrophobia) and its use has more than doubled over the past 10 years.¹² Possible explanations

of the reduced performance in functional assessment should consider the substantial differences in LV assessment between the various imaging modalities. First of all, with the exception of the newest whole-heart 320-slice scanner, CT acquires the cardiac volume in more heartbeats in contrast to echocardiography, by which LV evaluation is performed on a single heart beat acquisition. Furthermore, β-blockers commonly administered prior to cardiovascular and coronary CT scans to lower heart rate and limit cardiac motion-related artefacts, may directly affect the evaluation of LV function. Finally, most studies evaluating 2DE and 3DE have commonly excluded patients with poor echocardiographic views, leading to an overestimation of echocardiographic accuracy compared to routine practice. When good images are available, 3DE improves the accuracy and reproducibility of LV volume and EF measurements overall.2

In addition to these considerations, although CMR is the gold standard for LV quantification, there still are significant limitations in LV quantification when comparing

		ИДСТ			MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean		Total	Mean		Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% Cl
5.1.1 2007-2009	meun	50	Total	Mean	50	Total	Weight	11,11,20, 55/6 61	reur	
Brodoefel 2007	148.6	55.2	20	146.4	56.6	20	0.7%	2.20 [-32.45, 36.85]	2007	
Schlosser 2007	164.2	52.5	21	144.2	46.7	21	1.0%	20.00 [-10.05, 50.05]		
Bastarrika 2008	113.47		12		20.71	12	2.7%	16.59 [-1.50, 34.68]		
Busch 2008	135.8	41.9	15	132.1	40.8	15	1.0%	3.70 [-25.90, 33.30]		
Puesken 2008	159.3	54.8	28	178.8	63.2	28		-19.50 [-50.48, 11.48]		
Wu 2008	171.2	73.9	41	172.2	74.8	41	0.9%	-1.00 [-33.19, 31.19]		
Akram 2009	121.9	35.7	20	117.2	24.6	20	2.5%	4.70 [-14.30, 23.70]		
Guo 2009	193.7	77.8	51	188	72.8	51	1.0%	5.70 [-23.54, 34.94]		
Sarwar 2009	118	21	21	115	20	21	5.8%	3.00 [-9.40, 15.40]		
Subtotal (95% CI)			229			229	16.5%	5.21 [-2.13, 12.54]		•
Heterogeneity: Chi ² =	= 5.20, df	= 8 (P =	= 0.74)	$ 1^2 = 0\%$						
Test for overall effect	: Z = 1.39	P = 0	16)	• 184 · 1940.0						
5.1.2 >2009										
Palumbo 2010	71	19	181	74	23	181	47.1%	-3.00 [-7.35, 1.35]	2010	
De Jonge 2011	185.2	53.2	26	188	52	26	1.1%	-2.80 [-31.40, 25.80]	2011	
Lee 2012	113.27	27.77	30	114.88	25.76	30	4.8%	-1.61 [-15.16, 11.94]	2012	-
Takx 2012	156.9	43.1	20	158.9	45.9	20	1.2%	-2.00 [-29.59, 25.59]	2012	
Brodoefel 2012	151.6	53.6	20	147.5	54.9	20	0.8%	4.10 [-29.53, 37.73]	2012	
Arraiza 2012	102.7	23	25	103.8	25.5	25	4.9%	-1.10 [-14.56, 12.36]	2012	
Bak 2012	167.4	81.9	111	183.3	94	111	1.7%	-15.90 [-39.09, 7.29]	2012	
Fuchs 2012	164	43	53	162	41	53	3.5%	2.00 [-14.00, 18.00]	2012	
Greupner 2012	137.3	50	36	131.1	59.4	36	1.4%	6.20 [-19.16, 31.56]	2012	
Maffei 2012	74	21	79	76	25	79	17.1%	-2.00 [-9.20, 5.20]	2012	+
Subtotal (95% CI)			581			581	83.5%	-2.41 [-5.68, 0.85]		•
Heterogeneity: Chi ² =	= 2.31, df	= 9 (P =	= 0.99)	; $I^2 = 0\%$						
Test for overall effect	: Z = 1.45	5 (P = 0)	15)							
Total (95% CI)			810			810	100.0%	-1.16 [-4.14, 1.83]		•
Heterogeneity: Chi ² =	,			$(00); I^2 = 0$)%					
	: Z = 0.76	5 (P = 0)	45)							-100 -50 0 50 100 MRI larger MDCT larger

Figure 11 Left ventricular end-diastolic volume: CT versus CMR. CMR, cardiac MR.

		IDCT			MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
5.2.1 2007-2009										
Schlosser 2007	77.3	46.6	21		47.3	21	0.7%	13.50 [-14.90, 41.90]		
Brodoefel 2007	70.5	35.2	20		35.8	20	1.1%	1.40 [-20.60, 23.40]		
Bastarrika 2008	35.43	6.42	12			12	18.7%	4.94 [-0.36, 10.24]		
Puesken 2008	71.8	47.8	28	82.5		28		-10.70 [-38.08, 16.68]		
Wu 2008	94.8	68.3	41		68.7	41	0.6%	0.90 [-28.75, 30.55]		
Busch 2008	54.9	29.6	15		27.3	15	1.3%	-2.70 [-23.08, 17.68]		
Akram 2009	42.5	16.6	20		14.6	20	5.6%	0.00 [-9.69, 9.69]		
Sarwar 2009	51	15	21	51	15	21	6.4%	0.00 [-9.07, 9.07]		
Guo 2009	94.5	44.3	51	92.9	42	51	1.9%	1.60 [-15.15, 18.35]	2009	- <u>-</u> -
Subtotal (95% CI)			229			229	36.8%	2.59 [-1.19, 6.36]		•
Heterogeneity: Chi ² =	- 3.11, di	f = 8 (P	= 0.93	$(3); ^2 = 0$)%					
Test for overall effect	: Z = 1.3	4 (P = 0)	0.18)							
5.2.2 >2009										
Palumbo 2010	35	18	181	36	22	181	30.6%	-1.00 [-5.14, 3.14]	2010	• •
De Jonge 2011	74.2	25	26	81	27	26	2.6%	-6.80 [-20.94, 7.34]		
Maffei 2012	37	19	79	38	23	79	12.1%	-1.00 [-7.58, 5.58]		
Takx 2012	66.4	42.8	20	60.7	45.7	20	0.7%	5.70 [-21.74, 33.14]		
Arraiza 2012	37.9	19	25		18.5	25	4.9%	1.20 [-9.20, 11.60]		
Bak 2012	60.2	49.4	111		49.4	111	3.1%	-7.20 [-20.20, 5.80]		
Greupner 2012	65.7	51.7	36	65.6	61.9	36	0.8%	0.10 [-26.25, 26.45]		
Fuchs 2012	66	36	53	74	34	53	3.0%	-8.00 [-21.33, 5.33]		
Brodoefel 2012	69.2	32.7	20	67.5	32.9	20	1.3%	1.70 [-18.63, 22.03]		
Lee 2012	42.86	22.57	30	45.61	21.9	30	4.1%	-2.75 [-14.00, 8.50]		
Subtotal (95% CI)			581			581	63.2%	-1.68 [-4.56, 1.21]		•
Heterogeneity: Chi ² =	2.94. df	f = 9 (P)	= 0.97	7): $ ^2 = 0$)%					
Test for overall effect				,,						
Total (95% CI)			810			810	100.0%	-0.11 [-2.40, 2.18]		4
Heterogeneity: $Chi^2 =$	014 4	- 18 ($(6) \cdot 1^2 -$	0%	010	_00.070	5.11 [1.10, 1.10]		+ + + + + + + + + + + + + + + + + + + +
Test for overall effect				, i =	0/0					-100 -50 0 50 10
Test for subgroup dif				df = 1	P – 0	0.0) 12	- 67 7%			MRI larger MDCT larger
rescior subgroup an	referices		5.10,	ui = 1 (r = 0.	08), 1**	= 07.7%			

Figure 12 Left ventricular end-systolic volume: CT versus CMR. CMR, cardiac MR.

Open Heart: first published as 10.1136/openhrt-2015-000388 on 27 April 2016. Downloaded from https://openheart.bmj.com on 14 June 2025 by guest. Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	Ν	IDCT			MRI			Mean Difference		Mean Difference
Study or Subgroup	Mean		Total	Mean		Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% Cl
5.3.1 2007-2009										
Schlosser 2007	55.4	11.8	21	59.3	15.4	21	1.7%	-3.90 [-12.20, 4.40]	2007	
Brodoefel 2007	54.1	10.4	20	54.8	11.1	20	2.6%	-0.70 [-7.37, 5.97]	2007	
Wu 2008	50.4	19	41	51.4	18.8	41	1.7%	-1.00 [-9.18, 7.18]	2008	
Bastarrika 2008	68.19	4.52	12	68.53	2.85	12	12.7%	-0.34 [-3.36, 2.68]	2008	
Puesken 2008	58.1	16.8	28	57.3	15.7	28	1.6%	0.80 [-7.72, 9.32]	2008	
Busch 2008	61.6	12.4	15	57.9	9	15	1.9%	3.70 [-4.05, 11.45]	2008	
Sarwar 2009	57	8	21	55	8	21	4.9%	2.00 [-2.84, 6.84]	2009	
Akram 2009	65.3	8.7	20	64.4	8	20	4.3%	0.90 [-4.28, 6.08]	2009	_
Guo 2009	51.8	10.3	51	50.5	9.9	51	7.5%	1.30 [-2.62, 5.22]	2009	- <u>+</u>
Subtotal (95% CI)			229			229	39.0%	0.45 [-1.27, 2.17]		•
Heterogeneity: Chi ² =	2.84, d	f = 8 (P = 0.9	(4); $I^2 =$	0%					
Test for overall effect	: Z = 0.5	51 (P =	= 0.61)							
5.3.2 >2009										
Palumbo 2010	53	15	181	53	14	181	13.0%	0.00 [-2.99, 2.99]		-
De Jonge 2011	60.6	8.2	26	57	8	26	6.0%	3.60 [-0.80, 8.00]		
Bak 2012	67.1	9.5	111	66	9.5	111	18.5%	1.10 [-1.40, 3.60]	2012	
Brodoefel 2012	56	9	20	56	10	20	3.3%	0.00 [-5.90, 5.90]	2012	
Arraiza 2012		10.8	25		10.7	25	3.3%	-1.60 [-7.56, 4.36]		
Takx 2012		14.8	20		14.6	20		-5.10 [-14.21, 4.01]	2012	
Fuchs 2012	61	11	53	56	10	53	7.2%	5.00 [1.00, 9.00]		
Greupner 2012		14.7	36	55.6	16	36	2.3%	1.30 [-5.80, 8.40]	2012	
Maffei 2012	52	14	79	52	14	79	6.1%	0.00 [-4.37, 4.37]	2012	
Subtotal (95% CI)			551			551	61.0%	1.13 [-0.25, 2.50]		•
Heterogeneity: Chi ² =				$(0); I^2 =$	4%					
Test for overall effect	Z = 1.6	50 (P =	= 0.11)							
Total (95% CI)			780			780	100.0%	0.86 [-0.21, 1.94]		•
Heterogeneity: $Chi^2 =$	11 55	df – 1		0 83) 12	² – 0%					
Test for overall effect				0.05), 1	- 0/0					-20 -10 0 10 20
Test for subgroup dif				df = 1	$(\mathbf{P} = 0)$) 5 5) 1 ²	- 0%			MRI larger MDCT larger
rescion subgroup un	referices	. Chi	- 0.30	, ui – 1	r = 0	,,, I	- 0/0			

Figure 13 Left ventricular ejection fraction: CT versus CMR. CMR, cardiac MR.

imaging techniques by setting CMR parameters as true values for bias estimation, such as basal slice selection and multiple breath-holds acquisition. Moreover, most clinical studies, and indeed clinical practice, are based on echocardiographic parameters, and 2DE cut-offs for EF are the most often reported and relied on.^{21–23} Although CMR parameters are compared to well-established normality databases,^{24–25} the data on patient management and outcome based on CMR are still limited. However, up to date CMR remains the highest reproducible LV quantification modality.²⁶ Technical advances are allowing better semiautomatic acquisition and analysis for higher operator independency,^{27–28} and direct prognostic evidence with CMR is growing.^{29–30}

Limitations

The majority of studies included a small number of patients with different baseline characteristics. Most of the studies analysed were single-centre retrospective trials, and, therefore, issues of potential referral bias and inconsistent data collection may be present. As in any meta-analysis, the validity of our results is dependent on the validity of the studies included but this variability reflects clinical practice. There are multiple risks of bias in systematic reviews; however, our funnel plot analyses mostly demonstrated no significant publication bias for the results without significant heterogeneity, except for 2DE. A few studies had to be excluded due to different numbers of patients undergoing different modalities. Technical issues in completing the scans mainly caused this inconsistency. We excluded these studies to keep the balance between the modality groups. Some studies did not report LVEF but only presented volumes. We chose to include these since the analyses for LV volumes and LVEF were performed separately and consequently we considered them as independent parameters. We did restrict inclusion of the CT studies to recent technology only, and did not do this for the echo studies. The advances in CT imaging over this time period have been substantial, and more so than echo. Nevertheless, in the analyses, we have subgrouped the studies by year of publication to partially account for this, and no chronological impact is apparent.

Conclusion

Comparing commonly available non-invasive imaging modalities to CMR as a reference standard, 3DE holds the highest accuracy in LVEF estimation, although 2DE and 3DE-derived LV volumes are significantly underestimated. Newer generation CT shows excellent accuracy for LV volumes quantification. These results may help clinicians to better understand the degree of absolute bias between different cardiac imaging modalities and may have potential implications for patient follow-up and management.

Author affiliations

¹Awhina Health Campus, Waitemata District Health Board, Auckland, New Zealand

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

²Department of Medicine, Section of Cardiology, University of Verona, Verona, Italv

³Institute of Diagnostic Ultrasound, Australasian Sonographers Association, Melbourne, Victoria, Australia

Twitter Follow Gillian Whalley at @GWhalleyPhD

Acknowledgements The authors thank the following people for providing additional data or confirming the data we had extracted from their studies: Dr Antonio Abbate, Dr Michael Chuang, Dr Ana Garcia-Alvarez, Dr Ola Giessdal, Dr Sigrun Halvorsen. Dr Carly Jenkins. Dr Jens Kastrup. Dr Bernhard Metzler. Dr Masaaki Takeuchi, Dr Victor Mor-Avi, Dr Jürgan Scharhag, Dr Marta Sitges, Dr Osama Soliman, Dr Stefan Steorck and Dr Cezary Szmigielski.

Contributors MR and SA conducted the searches. All four authors developed the search strategy. MR drafted the first manuscript, and SA. GAW and JPC offered feedback and edited the final version. All the authors contributed to the design and conduct of the study and have approved this final version.

Funding This study was funded by Awhina Knowledge and Innovation Centre. Waitemata District Health Board (summer studentship).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Our data are limited to the group level data for the individual studies we used. Some of these were easily, and some not so easily, accessible. We would be happy to share our data.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/4.0/

REFERENCES

- Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC 1. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart 2015;36:2793-867.
- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline 2 for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014:129:e521-643.
- McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for З. the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
- Taylor GJ, Humphries JO, Mellits ED, et al. Predictors of clinical 4. course, coronary anatomy and left ventricular function after recovery from acute myocardial infarction. Circulation 1980;62:960-70.
- 5. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
- Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/ 6. SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;121:2462-508
- Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left 7. ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000:21:1387-96
- Dorosz JL. Lezotte DC. Weitzenkamp DA. et al. Performance of 8. 3-dimensional echocardiography in measuring left ventricular

volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:1799-808.

- 9. Shimada YJ, Shiota T. A meta-analysis and investigation for the source of bias of left ventricular volumes and function by three-dimensional echocardiography in comparison with magnetic resonance imaging. Am J Cardiol 2011;107:126-38.
- Jenkins C, Bricknell K, Hanekom L, et al. Reproducibility and 10 accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004:44:878-86.
- Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ 11. ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Cardiovasc Comput Tomogr 2010;4:407.e1-33.
- Halliburton SS, Abbara S, Chen MY, et al. SCCT guidelines on 12 radiation dose and dose-optimization strategies in cardiovascular CT. J Cardiovasc Comput Tomogr 2011;5:198-224.
- Achenbach S, Marwan M, Ropers D, et al. Coronary computed 13. tomography angiography with a consistent dose below 1 mSv using prospectively electrocardiogram-triggered high-pitch spiral acquisition. Eur Heart J 2010;31:340-6.
- Greupner J, Zimmermann E, Grohmann A, et al. Head-to-head 14. comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard. J Am Coll Cardiol 2012;59:1897-907.
- 15. Jenkins C, Moir S, Chan J, et al. Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J 2009;30:98-106.
- 16. Chukwu EO. Barasch E. Mihalatos DG. et al. Relative importance of errors in left ventricular quantitation by two-dimensional echocardiography: insights from three-dimensional echocardiography and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2008;21:990-7.
- Mor-Avi V, Jenkins C, Kuhl HP, et al. Real-time 3-dimensional 17. echocardiographic quantification of left ventricular volumes: multicenter study for validation with magnetic resonance imaging and investigation of sources of error. JACC Cardiovasc Imaging 2008:1:413-23
- Asferg C, Usinger L, Kristensen TS, et al. Accuracy of multi-slice 18 computed tomography for measurement of left ventricular ejection fraction compared with cardiac magnetic resonance imaging and two-dimensional transthoracic echocardiography: a systematic review and meta-analysis. Eur J Radiol 2012;81:e757-62
- Van der Vleuten PA, Willems TP, Gotte MJ, *et al.* Quantification of 19. global left ventricular function: comparison of multidetector computed tomography and magnetic resonance imaging. A meta-analysis and review of the current literature. Acta Radiol 2006:47:1049-57.
- 20 Ruddox V, Mathisenc M, Bækkevarb M, et al. Is 3D echocardiography superior to 2D echocardiography in general practice? A systematic review of studies published between 2007 and 2012. Int J Cardiol 2013;168:1306–15.
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable 21. cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005:352:225-37
- 22. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
- 23. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
- 24. Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:775-82.
- 25. Maceira AM, Prasad SK, Khan M, et al. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006;8:417-26.
- 26. Danilouchkine MG, Westenberg JJ, de Roos A, et al. Operator induced variability in cardiovascular MR: left ventricular

Open Heart

measurements and their reproducibility. *J Cardiovasc Magn Reson* 2005;7:447–57.

- Nassenstein K, de Greiff A, Hunold P. MR evaluation of left ventricular volumes and function: threshold-based 3D segmentation versus short-axis planimetry. *Invest Radiol* 2009;44:635–40.
 Lelieveldt BP, van der Geest RJ, Lamb HJ, *et al.* Automated
- Lelieveldt BP, van der Geest RJ, Lamb HJ, *et al.* Automated observer-independent acquisition of cardiac short-axis MR images: a pilot study. *Radiology* 2001;221:537–42.
- Bluemke DA, Kronmal RA, Lima JA, *et al.* The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol* 2008;52:2148–55.
- Gulati A, Ismail TF, Jabbour A, *et al.* The prevalence and prognostic significance of right ventricular systolic dysfunction in nonischemic dilated cardiomyopathy. *Circulation* 2013;128:1623–33.